Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Aug 11 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has received final approval from the USFDA for Diltiazem Hydrochloride Tablets in various strengths. These tablets are used for managing chronic stable angina and coronary artery spasm. The production will take place at Zydus's facility in Baddi, Himachal Pradesh.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 11, 2025, titled "Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg".

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases